OCU400

About Ocugen

Ocugen is a patient-centric biotech focused on developing transformative therapies for blinding retinal diseases and infectious diseases. Its core innovation is a modifier gene therapy platform that aims to reset retinal homeostasis, offering a single treatment for multiple genetic mutations. The company is advancing a diversified pipeline, with a Phase 3 asset in retinitis pigmentosa and strategic partnerships to bolster its development and commercial capabilities. Ocugen's strategy leverages deep ophthalmology and gene therapy expertise to address significant unmet medical needs.

Therapeutic Areas

Other Retinitis Pigmentosa Drugs